To explore the potential for a given HLA allele to produce an antiviral response, we assessed the HLA binding affinity of all possible 8-mers to 12-mers from the SARS-CoV-2 proteome (n = 48,395 unique peptides). We then removed from further consideration 16,138 peptides that were not predicted to enter the MHC class I antigen processing pathway via proteasomal cleavage. For the remaining 32,257 peptides, we repeated binding affinity predictions for a total of 145 different HLA types, and we show here the SARS-CoV-2-specific distribution of per-allele proteome presentation (predicted binding affinity threshold of <500 nM) (Fig. 1; see also Table S1 in the supplemental material). Importantly, we note that the putative capacity for SARS-CoV-2 antigen presentation is unrelated to the HLA allelic frequency in the population (Fig. 1). We identify HLA-B*46:01 as the HLA allele with the fewest predicted binding peptides for SARS-CoV-2. We performed the same analyses for the closely related SARS-CoV proteome (see Fig. S1 in the supplemental material) and similarly note that HLA-B*46:01 was predicted to present the fewest SARS-CoV peptides, in keeping with previous clinical data associating this allele with severe disease (49).